These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 18551268)

  • 1. [Long-term therapy of focal dystonia and facial hemispasm with botulinum toxin A].
    Vogt T; Lüssi F; Paul A; Urban P
    Nervenarzt; 2008 Aug; 79(8):912-7. PubMed ID: 18551268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH; Cetinkaya A; Kulwin DR
    Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum Toxin Treatment of Blepharospasm, Orofacial/Oromandibular Dystonia, and Hemifacial Spasm.
    Karp BI; Alter K
    Semin Neurol; 2016 Feb; 36(1):84-91. PubMed ID: 26866500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Botulinum toxin therapy for focal dystonia].
    Hahn K; Niklai E; Garzuly F; Szupera Z
    Orv Hetil; 2009 Jul; 150(29):1381-4. PubMed ID: 19581172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose treatment of cervical dystonia, blepharospasm and facial hemispasm with albumin-diluted botulinum toxin type A under EMG guidance. An open label study.
    Rollnik JD; Matzke M; Wohlfarth K; Dengler R; Bigalke H
    Eur Neurol; 2000; 43(1):9-12. PubMed ID: 10601802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Lacrimal film evaluation of patients with facial dystonia during botulinum toxin type A treatment].
    Costa PG; Cardoso IP; Saraiva FP; Raiza AC; Tanaka LK; Matayoshi S
    Arq Bras Oftalmol; 2006; 69(3):319-22. PubMed ID: 16936952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions.
    Ozer IS; Kuzu Kumcu M; Tezcan Aydemir S; Akbostanci MC
    Clin Neurol Neurosurg; 2021 Oct; 209():106889. PubMed ID: 34461363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of flexible onabotulinum toxin A treatment in facial dystonia.
    Bladen JC; Feldman I; Favor M; Dizon M; Litwin A; Malhotra R
    Eye (Lond); 2019 Mar; 33(3):349-352. PubMed ID: 30202071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.
    Cillino S; Raimondi G; Guépratte N; Damiani S; Cillino M; Di Pace F; Casuccio A
    Eye (Lond); 2010 Apr; 24(4):600-7. PubMed ID: 19648904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term botulinum toxin treatment of benign essential blepharospasm, hemifacial spasm, and Meige syndrome.
    Czyz CN; Burns JA; Petrie TP; Watkins JR; Cahill KV; Foster JA
    Am J Ophthalmol; 2013 Jul; 156(1):173-177.e2. PubMed ID: 23541393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin in the treatment of dystonias--a hospital based study.
    Gupta M; Singh G; Khwaja G
    J Assoc Physicians India; 2003 May; 51():447-53. PubMed ID: 12974424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin physiology in focal hand and cranial dystonia.
    Karp BI
    Toxins (Basel); 2012 Nov; 4(11):1404-14. PubMed ID: 23202323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features and response to botulinum toxin in primary and secondary hemifacial spasm.
    Pandey S; Jain S
    Neurol India; 2018; 66(4):1036-1042. PubMed ID: 30038089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
    Grosset DG; Tyrrell EG; Grosset KA
    J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin].
    Yabiku MM; Sartori Jde F; Sarraff EP; Osaki TH; Hossaka SK; Pereira CI; Freitas Wd; Osaki MH; Cariello AJ
    Arq Bras Oftalmol; 2011; 74(6):414-6. PubMed ID: 22331113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hemifacial spasm through the last three decades: From etiology to efficacy and safety of long-term botulinum toxin treatment.
    Herrero-Infante Y; Rodríguez-Sanz A; Máñez-Miró J; Vivancos-Matellano F
    Clin Neurol Neurosurg; 2021 Apr; 203():106555. PubMed ID: 33662742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of botulinum toxin type A in treatment of different forms of focal dystonias in the Serbian population: experience of the Botulinum Toxin Outpatients Department.
    Tomić A; Vujović B; Svetel M; Misković ND; Petrović I; Pekmezović T; Kostić VS
    Vojnosanit Pregl; 2015 Dec; 72(12):1069-73. PubMed ID: 26898029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is new in the era of focal dystonia treatment? Botulinum injections and more.
    Cetinkaya A; Brannan PA
    Curr Opin Ophthalmol; 2007 Sep; 18(5):424-9. PubMed ID: 17700237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term adherence and response to botulinum toxin in different indications.
    Lee JI; Jansen A; Samadzadeh S; Kahlen U; Moll M; Ringelstein M; Soncin G; Bigalke H; Aktas O; Moldovan AS; Waskoenig J; Jander S; Gliem M; Schnitzler A; Hartung HP; Hefter H; Albrecht P
    Ann Clin Transl Neurol; 2021 Jan; 8(1):15-28. PubMed ID: 33259153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Essential blepharospasm and hemifacial spasm: characteristic of the patient, botulinum toxin A treatment and literature review].
    Schellini SA; Matai O; Igami TZ; Padovani CR; Padovani CP
    Arq Bras Oftalmol; 2006; 69(1):23-6. PubMed ID: 16491229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.